Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA
Molecular Oncology · 2026
DOI: 10.1002/1878-0261.70145 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Oncology, 2026. Verfasst von Christoffer Trier Maansson und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biochemistry, Aarhus University Hospital, Denmark. Hauptthemen laut MEDLINE: Epigenesis, Genetic, Cell-Free Nucleic Acids, Neoplasms, Circulating Tumor DNA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 171 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kræftens Bekæmpelse, Novo Nordisk Fonden.
Abstract (Originalsprache)
Liquid biopsies containing circulating tumor DNA (ctDNA) are important biomarkers across several forms of cancer. The detection of mutations in cell‐free DNA (cfDNA) indicates the presence of ctDNA. However, unsatisfactory ctDNA mutation sensitivities, issues with sequencing errors, and clonal hematopoiesis variants have limited the clinical utility of mutation‐based ctDNA assays. Recently, a new avenue of cfDNA assays has been developed, focusing on cfDNA epigenetics. Here, we outline the recent advancements in cfDNA epigenetics, focusing on cfDNA methylation, fragmentomics, and post‐translational modifications (PTMs) of circulating nucleosomes. We present various methylation strategies concerning ctDNA detection and tissue of origin (TOO) analyses. cfDNA fragmentomics focuses on cfDNA fragment lengths, fragment end motifs, and nucleosome positioning to infer gene expression and estimate the ctDNA fraction. Lastly, we discuss the development of cell‐free chromatin immunoprecipitation of circulating nucleosomes with PTMs. This method has been implemented to detect tumor gene expression, TOO, and treatment resistance. Combining the epigenetic features of cfDNA will expand the utility of liquid biopsies to give a more comprehensive insight into tumor biology, treatment response, and resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Biochemistry, Aarhus University Hospital, Denmark.
- Department of Clinical Medicine, Aarhus University, Denmark.
- Department of Biomedicine, Aarhus University, Denmark.
ORCID-Profile: Christoffer Trier Maansson, Boe Sandahl Sorensen
Förderung
- Kræftens Bekæmpelse
- Novo Nordisk Fonden
Zitieren
APA
Maansson, C. T., Nielsen, A. L., & Sorensen, B. S. (2026). Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA. Molecular Oncology. https://doi.org/10.1002/1878-0261.70145
Vancouver
Maansson CT, Nielsen AL, Sorensen BS. Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA. Molecular Oncology. 2026. doi:10.1002/1878-0261.70145
BibTeX
@article{Maansson2026,
author = {Maansson, Christoffer Trier and Nielsen, Anders Lade and Sorensen, Boe Sandahl},
title = {Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA},
journal = {Molecular Oncology},
year = {2026},
doi = {10.1002/1878-0261.70145}
}
EUVIMED